Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Dapirolizumab pegol (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms RISE
- Sponsors UCB
- 15 Nov 2023 Results of post hoc analysis (from studies NCT01262365; n=249, NCT01261793; n=263 and NCT02804763; n=43) assessing Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE presented at the ACR Convergence 2023
- 15 Nov 2023 Results of a post-hoc analysis assessing impact of DZP on B cell and type I IFN pathways using data from phase 2b RISE trial in SLE presented at the ACR Convergence 2023
- 15 Nov 2023 Results of post hoc analysis evaluating the treatment effect of dapirolizumab pegol in subgroups of patients from the phase 2b RISE trial presented at the ACR Convergence 2023